Department of Functional Sciences, University of Medicine and Pharmacy "Victor Babes" Timisoara, Romania.
Curr Pharm Des. 2014;20(4):585-600. doi: 10.2174/138161282004140213145806.
Atherosclerotic cardiovascular disease is the leading cause of death in many developed countries. It is characterized by complex endocrine, paracrine and juxtacrine interactions between immune and vascular cells, as well as several tissues and organs. Oxidative stress and inflammation have an important role in the promotion of atherosclerotic cardiovascular disease. Considering the complicated mechanisms and signals involved in atherosclerosis, research is focused on blood-based biomarkers, gene-based markers, metabolomics and other potentially interesting approaches for biomarker discovery. These biomarkers can be introduced as routine diagnostic tests if they prove to be cost-effective and to predict future cardiovascular events. Given the overlap of circulating inflammatory and oxidative stress biomarkers in atherosclerosis and rheumatic diseases, we aim to overview their potential to screen cardiovascular risk and also to predict the evolution of associated rheumatic diseases.
动脉粥样硬化性心血管疾病是许多发达国家的主要死亡原因。它的特点是免疫和血管细胞之间以及几个组织和器官之间存在复杂的内分泌、旁分泌和近分泌相互作用。氧化应激和炎症在促进动脉粥样硬化性心血管疾病方面起着重要作用。考虑到动脉粥样硬化涉及的复杂机制和信号，研究集中在基于血液的生物标志物、基于基因的标志物、代谢组学和其他有潜力的生物标志物发现方法上。如果这些生物标志物具有成本效益并能预测未来的心血管事件，则可以将其引入常规诊断测试中。鉴于循环炎症和氧化应激生物标志物在动脉粥样硬化和风湿性疾病中的重叠，我们旨在概述它们筛查心血管风险的潜力，并预测相关风湿性疾病的演变。
